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FABP3
CD36Traditional schizophrenia pharmacotherapy remains a subjective trial and error process involving admin-
istration, titration and switching of drugs multiple times until an adequate response is achieved. Despite
this time-consuming and costly process, not all patients show an adequate response to treatment. As a
consequence, relapse is a common occurrence and early intervention is hampered. Here, we have
attempted to identify candidate blood biomarkers associated with drug response in 121 initially
antipsychotic-free recent-onset schizophrenia patients treated with widely-used antipsychotics, namely
olanzapine (n = 40), quetiapine (n = 23), risperidone (n = 30) and a mixture of these drugs (n = 28).
Patients were recruited and investigated as two separate cohorts to allow biomarker validation. Data
analysis showed the most significant relationship between pre-treatment levels of heart-type fatty acid
binding protein (H-FABP) and response to olanzapine (p = 0.008, F = 8.6, b = 70.4 in the discovery cohort
and p = 0.003, F = 15.2, b = 24.4 in the validation cohort, adjusted for relevant confounding variables). In
a functional follow-up analysis of this finding, we tested an independent cohort of 10 patients treatedwith
olanzapine and found that baseline levels of plasma H-FABP and expression of the binding partner for
H-FABP, fatty acid translocase (CD36), on monocytes predicted the reduction of psychotic symptoms
(p = 0.040, F = 6.0, b = 116.3 and p = 0.012, F = 11.9, b = 0.0054, respectively). We also identified a set of
serum molecules changed after treatment with antipsychotic medication, in particular olanzapine.
These molecules are predominantly involved in cellular development and metabolism. Taken together, our
findings suggest an association between biomarkers involved in fatty acid metabolism and response to
olanzapine,while other proteinsmay serve as surrogatemarkers associatedwith drug efficacy and side effects.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction The disorder is treated primarily with antipsychotic medicationSchizophrenia is a severe mental illness affecting at least 21
million people worldwide (World Health Organization, 2014).but the exact mechanism of action of these drugs remains largely
unknown. As a consequence, traditional schizophrenia pharma-
cotherapy can be a subjective trial and error process involving
administration, titration and switching of drugs multiple times
until an adequate response is achieved. This results in the problem
that not all patients respond well to initial treatment, with up to
50% of patients not responding or experiencing relapse (Robinson
et al., 1999).
Treatment with antipsychotic drugs has also been associated
with adverse side effects which can lead to health problems
and non-compliance (Dolder et al., 2002; Fenton et al., 1997;
Tandon et al., 2008). The effects of second-generation (atypical)
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done, include metabolic-related side effects such as weight gain,
hyperglycaemia, insulin resistance and type II diabetes mellitus
(Newcomer, 2005). Side effects of atypical antipsychotics have
been associated with the high affinity of these compounds for
histamine H1, a1 adrenergic, 5-hydroxytryptamine 2C (5-HT2C)
and 5-HT6 receptors, which are known to be involved in appetite
regulation (Kim et al., 2007; Kroeze et al., 2003). Considering the
potential negative health impact of these side effects, clinicians
are now required to monitor patients receiving atypical antipsy-
chotics closely for their glucose, insulin and fatty acid blood levels.
In addition, these deficits have led academic and pharmaceuti-
cal industry researchers to launch biomarker discovery initiatives
to facilitate treatment decisions and identify novel therapeutic
approaches. It is anticipated that the application of biomarker
strategies into the clinical decision making process could lead to
benefits such as better stratification of patients, monitoring of
therapeutic effects, or early detection of side effects (personalised
medicine). There have already been some molecular studies which
have investigated the association between antipsychotic treatment
effects and biomarker readouts (Choi et al., 2009; Schwarz et al.,
2012; Thomas, 2006). For example, changes in immune and meta-
bolic markers have been associated with psychotic relapse in
schizophrenia patients after treatment with atypical antipsy-
chotics (Schwarz et al., 2012).
With this in mind, we have attempted to characterise serum
molecular profiles in early stage schizophrenia patients, before
and after treatment with some of the most widely-used atypical
antipsychotics. We performed a comprehensive molecular analysis
on serum collected from recent-onset, drug-free schizophrenia
patients before and after treatment with olanzapine, risperidone,
quetiapine or a mixture of these antipsychotics. Sera were ana-
lyzed using the HumanMAPmultiplex immunoassay panel which
targets a selection of hormones, growth factors, transport proteins
and immune-related molecules, which may be relevant to the
antipsychotic mechanism of action. Proteins which showed signif-
icant predictive value for treatment response or alterations after
treatment were evaluated in an independent clinical cohort treated
with the same medications. In addition, we carried out functionalTable 1
Demographic details of schizophrenia patients from discovery, validation and follow-up coh
(4–6 weeks). Values are shown as mean ± standard deviation. nk = not known.
Discovery
Number 47
Treatment (ola/quet/risp/mix) 23/9/7/8
Gender (male/female) 35/12
Age (years) 29.0 ± 10.8
Body mass index (kg/m2) 22.6 ± 3.1a
Smoking (yes/no/nk) 6/16/25
Cannabis (yes/no/nk) 0/1/46
Treatment status (drug-naïve/free) 23/24
PANSS positive score T0 19.9 ± 6.8
PANSS negative score T0 19.0 ± 8.3
PANSS general psychopathology score T0 39.6 ± 10.3
PANSS total score T0 78.5 ± 22.2
PANSS positive score T1 13.4 ± 6.0
PANSS negative score T1 16.1 ± 7.9
PANSS general psychopathology score T1 31.3 ± 11.7
PANSS total score T1 60.8 ± 23.8
Cumulative chlorpromazine equivalent units T1 (mg):
Olanzapine nk
Quetiapine nk
Risperidone nk
Mixture nk
a Data available for 23 patients.
b Data available for 10 patients.
c Data available for 17 patients.follow-up study of the findings using blood cells isolated from an
independent cohort of recent-onset drug-naïve patients.
2. Materials and methods
2.1. Clinical samples
Subjects were recruited from the Departments of Psychiatry at
the Universities of Cologne (discovery cohort), Muenster
(discovery cohort), Magdeburg (validation cohort) and the Erasmus
Medical Centre in Rotterdam (follow-up cohort; Table 1).
Schizophrenia was diagnosed based on the Diagnostic and Statisti-
cal Manual of Mental Disorders IV (DSM-IV). The medical faculty
ethical committees of the respective universities approved the
protocols of the study. Informed consent was given in writing by
all participants and clinical investigations were conducted accord-
ing to the Declaration of Helsinki.
All patients were antipsychotic-naïve (n = 67) or had been free
of antipsychotic medication for at least 6 weeks at the start of
the study (n = 66). Patients with co-morbidities, such as type II
diabetes mellitus, hypertension, cardiovascular, autoimmune,
inflammatory or infectious diseases, were excluded from the
study. Patients were assessed for psychopathology by experienced
clinicians using the Positive and Negative Syndrome Scale (PANSS)
before and after 4–6 weeks treatment with antipsychotics.
2.2. Multiplex immunoassay profiling
Blood samples from the discovery and validation cohorts were
collected between 8:00 and 12:00 am into S-Monovette 7.5 mL
serum tubes (Sarstedt). Patients were not required to fast at the
time of blood collection. The blood was left at room temperature
for 2 h according to standard protocols to allow clotting and
centrifuged at 4000g for 5 min to remove particulate material.
Resulting supernatants were stored at 80 C in Low Binding
microcentrifuge tubes (Eppendorf). Levels of 147 analytes were
measured in 250 lL serum using the Human MAP multiplexed
immunoassay platform (Appendix A, Table A.1) in a Clinical
Laboratory Improvement Amendments (CLIA)-certified laboratoryorts. BMI – body mass index, T0 – baseline measurement, T1 – follow-up measurement
Validation Follow-up
74 12
17/14/23/20 12/0/0/0
50/24 12/0
35.4 ± 11.0 26.4 ± 6.2
25.3 ± 4.6 24.0 ± 4.8
49/25/0 8/4/0
16/52/6 2/10/0
32/42 12/0
23.1 ± 7.2 20.5 ± 5.3b
19.0 ± 8.6 22.1 ± 5.4b
42.9 ± 10.4 39.6 ± 6.0b
85.0 ± 20.3 82.2 ± 13.9b
12.7 ± 5.4 13.7 ± 4.8b
14.1 ± 6.9 19.8 ± 5.1b
28.6 ± 9.2 33.7 ± 8.6b
55.5 ± 18.7 67.2 ± 15.4b
19,211 ± 8919 nk
28,191 ± 16,404 –
12,290 ± 6293 –
17,716 ± 12,998c –
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(Schwarz et al., 2010).
2.3. Immunoassay analysis of human H-FABP
Whole blood was collected from fasting patients from the
follow-up cohort into 7.5 mL heparin tubes (Sarstedt), centrifuged
at 500 g for 10 min and the supernatants (plasma) were stored at
80 C. Plasma levels of H-FABP were determined using a human
H-FABP enzyme-linked immunosorbent assay (ELISA) kit (Hycult
Biotech) according to manufacturer’s protocol.
2.4. Flow cytometry
Peripheral blood mononuclear cells (PBMCs) were prepared
from blood collected into 7.5 mL heparin tubes from the follow-
up cohort, as above. The pellets containing blood cells after the
centrifugation step were diluted 1:1 with phosphate-buffered
saline (PBS; Sigma–Aldrich) and centrifuged over Ficoll (GE Health-
care) at 750 g for 20 min. PBMCs were extracted from the
interphase, washed three times with PBS at 300 g for 10 min and
cryopreserved in foetal bovine serum (FBS) containing 10%
dimethyl sulfoxide (Sigma–Aldrich) at 5  106 cells/mL. For analy-
sis, PBMCs were thawed at 37 C and suspended in pre-warmed
sterile RPMI-1640 medium (Sigma–Aldrich) containing 10% heat-
inactivated FBS, 50 U/mL penicillin and 50 lg/mL streptomycin,
2 mM L-alanyl-L-glutamine dipeptide (Life Technologies) and
20 lg/mL DNAse (Sigma–Aldrich). The cells were centrifuged at
500 g for 5 min and suspended at 1  106 cells/mL in 200 lL of
FACS buffer (PBS with 0.5% bovine serum albumin; Sigma Aldrich)
containing 20% human Fc receptor binding inhibitor (eBioscience)
to block non-specific antibody binding sites. Following 20 min
incubation at room temperature, 1  105 cells were stained with
0.5 lL anti-human CD3-PeCy7, 0.5 lL anti-human CD4-PerCP-
eFluor710, 0.5 lL anti-human CD8-APC-eFluor780 (eBioscience)
and 0.3 lL anti-human CD14-V500 (BD Biosciences) in a total
volume of 135 lL. Another 1  105 cells were stained for CD36
expression using the above staining cocktail plus 2.5 lL anti-
human CD36-eFluor660 (eBioscience) in a total volume of
135 lL. The cells were stained for 30 min in the dark at room
temperature, washed twice at 500 g for 5 min with 3 mL FACS
buffer and resuspended in 0.5 mL FACS buffer with 1 lM DAPI
(Sigma–Aldrich). A minimum of 40,000 cells were acquired from
each sample using an 8-colour BD FACSVerse flow cytometer (BD
Biosciences).
2.5. Data analysis
R version 2.15.2 (R Core Team, 2014) was used for statistical
analyses and FlowJo version 10 was used for analysis of flow
cytometry data. Treatment efficacy was determined by comparing
PANSS scores before and after treatment using Wilcoxon signed-
rank tests. Multiplex immunoassays with more than 30% missing
values (39 out of 147; Appendix A, Table A.1) were excluded from
further analysis. To account for values below and above the lower
and upper limits of detection, these were imputed with half the
minimum and 1.5 the maximum values, respectively. Association
of baseline molecular levels with response to treatment (DPANSS)
was determined using linear regression models after adjusting for
confounding factors. Relevant covariates were selected using
Bayesian Information Criterion. Age, gender and baseline PANSS
scores were included as optional covariates for all cohorts
(discovery, validation and follow-up) and body mass index (BMI),
smoking, cannabis use and treatment status (drug-free/naïve) were
included as optional covariates in the validation and follow-upcohorts only. DPANSS scores were calculated as percentages of
the baseline score (T0) after subtraction of the minimal possible
PANSS score (Leucht, 2014; Leucht et al., 2007). For linear
regression modelling, the values from the immunoassays were
log10-transformed to approximate normality. Distribution of ana-
lyte levels was assessed using Shapiro–Wilk tests. P values from
linear regression models were adjusted by unrestricted permuta-
tion of observations 1000 times (Manly, 2007). Due to known
association, a one-tailed Spearman’s rank correlation test was used
to calculate the correlation between plasma H-FABP levels and
monocyte CD36 expression. Wilcoxon signed-rank tests were used
to identify changes in protein levels following antipsychotic
treatment. Fold changes were calculated as the ratio of the mean
levels after and before treatment. P values were controlled for false
discovery rate (Q value) with the Benjamini–Hochberg procedure
(Benjamini and Hochberg, 1995). However, due to the exploratory
nature of this study, unadjusted P < 0.05 were considered
significant. In silico functional analysis was performed using the
Ingenuity Pathway Analysis software (IPA; Ingenuity Systems).3. Results
3.1. Patient characteristics and treatment efficacy
Patient samples in the discovery and validation cohorts were
matched for gender and the initial total PANSS scores (Table 1).
Cumulative antipsychotic doses at the follow-up time point did
not differ significantly between different treatment types in the
validation cohort, except being significantly higher in the group
treated with quetiapine than in the group treated with risperidone
(p < 0.01, Kruskal–Wallis test with post hoc Dunn’s multiple com-
parison tests). There was a significant decrease in PANSS general
psychopathology and total scores in both cohorts for all treatment
groups (Appendix A, Table A.2). However, the decrease in PANSS
positive scores was significant in both cohorts for patients treated
with olanzapine, risperidone and antipsychotic mixture, but not
after quetiapine treatment. Furthermore, the decrease in PANSS
negative scores was significant in both cohorts only after olanzap-
ine treatment.3.2. Prediction of response
Multiplexed immunoassay profiling of baseline molecular
levels for the four treatment groups allowed reproducible
identification of eight molecules, which could predict response
to antipsychotic medication. After controlling for relevant con-
founding factors, 2 out of an initial 8 predictions were validated
for response to olanzapine, 7 out of an initial 55 predictions were
validated for response to quetiapine, 1 out of an initial 64 predic-
tions was validated for treatment with risperidone and none out
of an initial 67 predictions was validated for mixed antipsychotic
treatment (Table 2). The most significant association across the
discovery and validation cohorts was observed between heart-
type fatty acid binding protein (H-FABP; UniProtKB ID P05413)
and response to olanzapine indicated by a change in total PANSS
scores. Higher baseline levels of H-FABP were associated with a
greater symptom reduction in the discovery (p = 0.008, F = 8.6,
b = 70.4; Fig. 1a) and validation (p = 0.003, F = 15.2, b = 24.4;
Fig. 1b) cohorts. Two molecules were reproducibly associated
with response in multiple symptom domains. H-FABP was
predicting improvement in negative and total PANSS scores for
treatment with olanzapine and interleukin-10 (IL-10) was pre-
dicting a change in positive and total PANSS scores for treatment
with quetiapine (Table 2).
Table 2
Predictors of change (D) in positive, negative, general psychopathology and total PANSS scores significant across the discovery and validation cohorts. The table shows values
adjusted for relevant confounding factors, as described in the Section 2. b – estimate from linear regression modelling; Q value – P value adjusted for false discovery rate.
Predictor (by treatment) Response variable Discovery Validation
b F value P value Q value b F value P value
Olanzapine:
Heart-type fatty acid binding protein DPANSS negative 60.6 5.5 0.030 0.998 90.2 19.7 0.012
Heart-type fatty acid binding protein DPANSS total 70.4 8.6 0.008 0.813 24.4 15.2 0.003
Quetiapine:
Angiotensinogen DPANSS negative 43.7 8.3 0.022 0.540 51.9 11.8 0.039
Insulin-like growth factor I DPANSS total 21.7 9.6 0.018 0.432 71.0 5.7 0.042
Interleukin-10 DPANSS positive 729.1 15.4 0.008 0.168 172.2 8.5 0.014
Interleukin-10 DPANSS total 489.5 8.8 0.026 0.432 114.8 10.6 0.016
Macrophage inflammatory protein-1 beta DPANSS positive 185.6 7.0 0.045 0.270 194.3 14.5 0.006
Receptor tyrosine kinase AXL DPANSS general 188.2 10.0 0.024 0.209 105.0 5.5 0.032
T-cell-specific protein RANTES DPANSS positive 159.7 11.5 0.019 0.187 200.0 13.2 0.006
Risperidone:
Thyroxine-binding globulin DPANSS negative 834.8 92.7 0.015 0.324 415.7 8.1 0.026
Fig. 1. The most significant predictor of response identified across the discovery and validation cohorts. Baseline H-FABP levels were associated with a reduction of total
PANSS scores in the discovery (a) and in the validation (b) cohorts of schizophrenia patients treated with olanzapine. In a follow-up study, monocyte CD36 expression was
found to be inversely correlated with plasma levels of H-FABP (c) and was predictive of improvement in psychotic symptoms (DPANSS positive; (d)). P, b and DPANSS values
were adjusted for relevant confounding factors as described in the Section 2. Black line and grey area represent the fitted model and its 95% confidence intervals, respectively.
q – Spearman’s rank correlation coefficient.
J. Tomasik et al. / Brain, Behavior, and Immunity 52 (2016) 178–186 181
182 J. Tomasik et al. / Brain, Behavior, and Immunity 52 (2016) 178–1863.3. Functional follow-up study
In an independent pilot study performed in 12 recent-onset ini-
tially drug-naïve patients treated with olanzapine (DPANSS data
was available for 10 of them), plasma levels of H-FABP predicted
change in total PANSS scores with borderline significance
(p = 0.089, F = 3.6, b = 60.8), significantly predicted the change in
PANSS positive scores (p = 0.040, F = 6.0, b = 116.3) and were nega-
tively correlated with CD36 expression in monocytes (p = 0.05,
q = 0.50; Fig. 1c). CD36 (UniProtKB ID P16671) is a fatty acid
translocase known to interact with H-FABP. Among the tested T
helper cells, T cytotoxic cells, B cells and monocytes, CD36 mole-
cules were predominantly expressed in the latter (Appendix B,
Fig. B.1). After controlling for relevant confounding variables,
monocyte CD36 expression predicted the reduction in PANSS total
scores with borderline significance (p = 0.080, F = 4.0, b = 0.0033)
and significantly predicted PANSS positive score reduction
(p = 0.012, F = 11.9, b = 0.0054; Fig. 1d).3.4. Treatment effects
In the discovery cohort, multiplexed immunoassay profiling led
to identification of 50 molecules with altered levels after treatment
with olanzapine (Appendix A, Table A.3), whereas only 5, 10 and 15
analytes were changed after the quetiapine, risperidone and mixed
antipsychotic treatments, respectively (Appendix A, Table A.4). The
highest number of consistent changes (P < 0.05, same directional
change) between the discovery and validation cohorts was
observed for the olanzapine treatment group. In both cohorts, the
levels of 14 proteins were increased and 3 were decreased
(Table 3). In addition, one protein [angiotensin-converting enzyme
(ACE)] which met the same criteria, was identified for the quetiap-
ine treatment and one (prolactin) for the risperidone treatment
groups. The mixed antipsychotic therapy resulted in significant
changes in two proteins, insulin-like growth factor binding protein
2 (IGFBP2) and prolactin. Finally, two proteins were reproduciblyTable 3
Consistency of changes revealed by multiplexed immunoassays between discovery and
Wilcoxon signed-rank test) with the same direction of change are shown. Q value – P val
Analyte (by treatment) UniProtKB ID Discovery
RC
Olanzapine:
Angiotensin-converting enzyme P12821 1.32
Alpha-fetoprotein P02771 1.37
Beta-2 microglobulin P61769 1.28
EN-RAGE P80511 0.67
Factor VII P08709 1.09
Fas (FASLG receptor) P25445 1.24
ICAM-1 P05362 1.28
MDC O00626 1.20
MMP-3 P08254 0.75
Prolactin P01236 1.52
Prostatic acid phosphatase P15309 1.30
Resistin Q9HD89 0.78
Stem cell factor P21583 1.16
Thyroid-stimulating hormone P01215 1.28
TNF-alpha P01375 1.50
TNF RII Q92956 1.58
VCAM-1 P19320 1.23
Mixture:
IGFBP2 P18065 0.74
Prolactin P01236 4.64
Quetiapine:
Angiotensin-converting enzyme P12821 1.28
Risperidone:
Prolactin P01236 3.84increased after treatment with different antipsychotic medica-
tions: prolactin (after treatment with olanzapine, risperidone and
antipsychotic mixture) and ACE (after treatment with olanzapine
and quetiapine).
Pathway analysis of combined multiplexed immunoassay data
from olanzapine-treated patients revealed that the most signifi-
cantly altered molecular and cellular functions were cell-to-cell
signalling, cellular development, cellular growth, proliferation
and movement (P values 5.35E09–3.64E03; with 9 or more
molecules involved in each function; Appendix A, Table A.5). The
top canonical pathway affected by the olanzapine treatment was
atherosclerosis signalling (P = 2.41E07; 5 proteins involved) and
the disorder that was most significant to the dataset was
cardiovascular disease (P values 3.98E08–3.28E03; 9 out of 17
molecules involved).4. Discussion
This is the first comprehensive protein profiling study to iden-
tify and validate serum biomarkers in recent-onset schizophrenia
patients associated with response prediction and molecular effects
of different antipsychotic treatments. Serum was collected from
121 drug-naïve and drug-free patients following four different
treatment regimes. On average, the patients showed reduction in
positive, negative and cognitive symptoms, with the most
significant changes observed following olanzapine treatment.
Multiplexed immunoassay analysis of 147 serum analytes before
and after therapy resulted in identification of 8 molecules
significantly associated with response to treatment, with the most
significant finding for H-FABP as a baseline predictor of response to
olanzapine. This was followed-up at the functional level using
samples from 10 drug-naïve patients with the finding that plasma
H-FABP levels and monocyte expression of the H-FABP molecular
partner, CD36, predicted changes in psychotic symptoms after
treatment with olanzapine. Importantly, the analyses were con-
trolled for a number of potential confounding factors, includingvalidation cohorts for four different treatments. Only significant changes (P < 0.05,
ue adjusted for false discovery rate; RC – ratio change.
Validation
P value Q value RC P value
0.001 0.005 1.42 <0.001
<0.001 0.002 1.66 0.008
<0.001 0.002 1.15 0.006
0.033 0.069 0.59 0.005
0.029 0.064 1.27 0.004
0.001 0.004 1.25 0.001
0.001 0.004 1.28 0.005
0.002 0.009 1.31 0.001
0.028 0.063 0.38 <0.001
0.015 0.037 4.04 <0.001
0.001 0.007 1.43 0.002
0.006 0.019 0.83 0.001
0.013 0.034 1.24 0.006
0.031 0.067 1.83 <0.001
<0.001 0.002 2.03 0.013
<0.001 <0.001 1.22 0.001
<0.001 0.002 1.13 0.016
0.035 0.338 0.79 0.035
0.016 0.315 2.04 0.011
0.024 0.694 1.28 0.002
0.016 0.394 3.96 <0.001
Fig. 2. Hypothetical mechanism of the interaction between fatty acid handling proteins H–FABP and CD36 and response to olanzapine. H-FABP is a critical factor for
arachidonic acid (AA) transport and metabolism (Hanhoff et al., 2002), especially in the brain (Shioda et al., 2014). Also CD36 is known to mediate AA uptake inside the cell
(Dutta-Roy et al., 1996). Alterations in AA transport may result in altered membrane fluidity, which affects receptor function, or in impaired signal transduction from
dopamine D2 (D2R) and 5-hydroxytryptamine 2 (5-HT2R) receptors, for which AA acts as a second messenger (Piomelli et al., 1991; Qu et al., 2005). This could
diminish response to antipsychotic treatment and other processes. Other abbreviations: 5-LOX – 5-lipoxygenase, COX – cyclooxygenase, CYP – cytochrome P450,
PC – phosphatidylcholine, PE – phosphatidylethanolamine, PI – phosphatidylinositol, PKC – protein kinase C, PLA2 – phospholipase A2, PLC – phospholipase C.
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use and medication status. Moreover, the identified associations
were also significant without correcting for covariates, except the
association between H-FABP and change in positive symptoms in
the follow-up cohort (uncorrected p = 0.076). It should be noted
that the groups treated with quetiapine, risperidone and mixed
antipsychotics in the discovery cohort had low sample sizes, there-
fore results for these three treatment types should be considered
with more caution.
The most significant predictor of response, H-FABP, is a lipid
carrier protein expressed primarily in cardiac and skeletal muscles,
brain, and mammary gland (Furuhashi and Hotamisligil, 2008). At
concentrations >17.7 ng/ml, this protein has been used as a
biomarker for acute coronary syndrome (Gururajan et al., 2010).
However, across the 52 patients treated with olanzapine in the
current study, we found that samples from only 3 individuals
had H-FABP concentrations exceeding this threshold. Furthermore,
patients with a diagnosis of cardiovascular disease had been
excluded from analysis in this study, making it unlikely that these
effects were associated with such conditions. Changes in H-FABP
levels have also been identified in post-mortem studies of other
brain disorders. Decreased levels of H-FABP have been found in
brain tissues from patients with Down’s syndrome and Alzheimer’s
disease (Cheon et al., 2003). The same researchers suggested that
H-FABP may affect brain function by altering membrane fluidity
and, therefore, signal transduction in neuronal cells (Cheon et al.,
2003). More recently, H-FABP has been shown to be highly
expressed in dopaminergic neurons (Shioda et al., 2014) and regu-
late dopamine D2 receptor function (Shioda et al., 2010) as well assynaptogenesis and myelination (Liu et al., 2010) in animal models.
This is interesting considering the proposed role of elevated
dopamine levels in schizophrenia (Meltzer and Stahl, 1976).
CD36 (or fatty acid translocase) is a membrane protein
expressed by many cell types, which binds to a variety of ligands
including thrombospondin, long-chain fatty acids, oxidised low
density lipoproteins and pathogen associated molecular patterns
(Moulle et al., 2012). It is involved in fatty acid and glucose meta-
bolism, and has been linked to insulin resistance (Hajri et al.,
2002). CD36 and H-FABP are known to physically interact in vivo
(Spitsberg et al., 1995) and contain similar fatty acid-binding
domains (Baillie et al., 1996). We showed that levels of H-FABP
and monocyte CD36 were inversely correlated and patients with
low concentrations of H-FABP and high expression of CD36 on
monocytes were less likely to respond to olanzapine. We suggest
that low treatment response may be due to a deregulation of signal
transduction in these patients involving fatty acid transport or
metabolism (Fig. 2). This is consistent with studies which have
shown that cell membrane fatty acids can be depleted in some
schizophrenia patients and higher intake of unsaturated fatty acids
has been associated with less severe symptoms (Laugharne et al.,
1996). Pre-treatment lipid levels have also been shown to be
different between responders and non-responders to atypical
antipsychotic treatment (Kaddurah-Daouk et al., 2007). Taken
together, these findings suggest that fatty acid metabolism affects
signal transduction in the brain and peripheral H-FABP and
monocyte CD36 levels could provide a good indicator of response
to olanzapine treatment and represent potential therapeutic
targets (Furuhashi and Hotamisligil, 2008; Moulle et al., 2012).
184 J. Tomasik et al. / Brain, Behavior, and Immunity 52 (2016) 178–186Our results also suggest a potential role for the immune system
in response to antipsychotic medication. It is interesting that
cyclooxygenase (COX) is one of the proteins downstream the iden-
tified fatty acidmetabolism pathway (Fig. 2). COX is an enzyme that
produces prostaglandins and mediates inflammation. It has been
shown that modulation of COX activity with anti-inflammatory
agents such as aspirin and celecoxib may improve symptoms in
schizophrenia patients (Akhondzadeh et al., 2007; Laan et al.,
2010; Muller et al., 2010). In addition, a number of immune-
related molecules in the present study were directly associated
with response to quetiapine. In particular, pre-treatment levels of
IL-10 predicted changes in positive and total PANSS scores. IL-10
is gaining increased attention in schizophrenia because of its
genetic association with the disease (Bocchio Chiavetto et al.,
2002; Ozbey et al., 2009) and the fact that serum levels of IL-10 cor-
relate with psychopathology in schizophrenia patients (de Witte
et al., 2014; Xiu et al., 2014). Our findings add to this evidence
and support current efforts to increase response rate to antipsy-
chotic medication with add-on immunomodulatory agents.
Although all tested antipsychotics belonged to the atypical class
of neuroleptics, the findings did not reproduce between different
treatment types. This suggests that the identified predictors may
be specific to a specific medication and interact with the drug
mechanism of action. In this context, it is not surprising that no
predictors were identified for treatment with mixed antipsychotic
medication, where patients were prescribed multiple antipsy-
chotics, either simultaneously (polypharmacy) or sequentially.
Nevertheless, the exact mechanisms of interaction between the
identified predictors and different treatments remain unclear and
require further evaluation.
Multiplexed immunoassay profiling of patient serum revealed
also molecular changes associated with different atypical antipsy-
chotic treatments. Common effects of therapy with different
atypical antipsychotics included increased prolactin and ACE
levels. The highest number of consistent changes was observed
after treatment with olanzapine, which resulted in changes in
the levels of 17 proteins. Pathway analysis indicated that these
proteins were most significantly involved in cell signalling, devel-
opment, growth and cardiovascular system regulation. We propose
that these effects may be associated with response to treatment in
terms of therapeutic efficacy and metabolic side effects, and that
the identified biomarkers could have utility for critical decision
making during antipsychotic treatment of first and early-onset
schizophrenia patients.
Prolactin and ACE were altered after treatment with different
atypical antipsychotics, which could be related to the clinical
effects of these compounds. Prolactin levels were increased signif-
icantly following treatment with olanzapine, risperidone and
mixed antipsychotic drugs. Prolactin is a peptide hormone pro-
duced by the pituitary gland and lymphocytes (Ben-Jonathan
et al., 1996). It is involved in many functions including lactation,
immune modulation and behavioural modification. It is also
known to be involved in stimulation of insulin release from
pancreatic b cells, which may explain why many patients treated
with these compounds develop insulin resistance (Ben-Jonathan
et al., 2006). An increase in prolactin levels following typical
antipsychotic treatment is well known and has also been ascribed
to the antagonistic activity of some atypical antipsychotics such as
olanzapine on dopamine D2 receptors in the anterior pituitary
(Kryzhanovskaya et al., 2009). These receptors regulate the
prolactin production and release and, therefore, high levels of this
hormone could be related to therapeutic outcome or metabolic
side effects of antipsychotic treatment (de Visser et al., 2001;
Kapur et al., 2000). Our study also confirmed previous reports that
treatment with quetiapine does not affect prolactin levels (Atmaca
et al., 2002; Leucht et al., 2013).The finding that ACE was increased after treatment with olanza-
pine and quetiapine is interesting as this protein normally facili-
tates vasoconstriction by catalysing conversion of angiotensin I
to angiotensin II. Therefore, the increased levels of this protein
may be involved in adverse cardiovascular side effects which are
sometimes associated with antipsychotic treatment, in particular
olanzapine (Daumit et al., 2008; Newcomer, 2007). In addition,
the in silico pathway analysis identified cardiovascular disease as
the top disorder associated with the molecular changes observed
after treatment with olanzapine, and atherosclerosis signalling as
the top canonical pathway related to those changes. Further
studies should be undertaken to determine the potential use of
ACE measurement as an early indicator of cardiovascular side
effects associated with antipsychotic treatment.
Although the affected proteins were measured in the blood,
some may also regulate function of cells within the central nervous
system. For example, MMP-3 is produced by microglia and macro-
phages and is known to induce white matter injury in patients
with vascular dementia (Rosenberg et al., 2001) and also to cause
de-myelination (Rosenberg, 2009). Therefore, the decreased levels
of MMP-3 observed following olanzapine treatment may be
associated with improved myelination. This is consistent with
the pro-myelination effects of some atypical antipsychotics, which
have been described previously (Bartzokis et al., 2007).
We also identified biomarkers that may be related to the meta-
bolic side effect profile of olanzapine. This included increased
levels of thyroid-stimulating hormone, which stimulates appetite
and may be at least partly responsible for drug-induced weight
gain (Khan et al., 2009). The olanzapine treatment also showed
changes in the levels of tumour necrosis factor (TNF)-alpha and
TNF RII, which have been implicated in weight gain during antipsy-
chotic treatment (Kluge et al., 2009). Additionally, treatment with
a mixture of antipsychotics resulted in decreased levels of IGFBP2,
which is known to have anti-diabetic effects in animal models
(Hedbacker et al., 2010). Taken together, these findings indicate
that there is considerable scope for further studies in the identifi-
cation of serum biomarkers which are associated with metabolic
side effects of atypical antipsychotics.
There are potential limitations which should be considered in
this study. Firstly, strict inclusion criteria pose an issue for the
external validity of the study and potential personalised medicine
applications. Findings presented here should not be generalised
before validating them in a more naturalistic setup and larger
patient cohorts. Secondly, the fact that olanzapine showed superior
therapeutic efficacy compared to the other antipsychotics could be
due to the smaller number of patients in other treatment groups. In
addition, it is conceivable that this would also lead to a greater
number of changes in serum biomarkers. Thirdly, response to
antipsychotics may be affected by many additional factors not
controlled for in these analyses, such as concomitant medication
or thyroid status. It should also be noted that patients in the
discovery and validation cohorts were not required to fast at
the time of blood collection. This might have affected levels of
some of the measured analytes, including H-FABP. However,
fasting blood sugar levels have been shown before to have negligi-
ble effect on serum H-FABP levels (Niizeki et al., 2007).5. Conclusions
The present results constitute the first comprehensive protein
profiling study to identify and validate the effects of treatment
with different atypical antipsychotics in recent-onset schizophre-
nia patients. This revealed that fatty acid handling proteins,
H-FABP and its binding partner monocyte CD36, could be used as
potential pre-treatment predictors of response to olanzapine. The
J. Tomasik et al. / Brain, Behavior, and Immunity 52 (2016) 178–186 185results also showed that prolactin and ACE levels were increased in
common by different treatment protocols and the highest number
of consistent changes was observed after treatment with olanzap-
ine. We suggest that these effects may be associated with response
to treatment and that the identified biomarkers could be useful to
guide critical decision making for the selection of antipsychotic
treatments of schizophrenia patients. Further molecular profiling
studies, such as the one described here, can help to increase our
understanding of the molecular basis of drug action as well as
disease processes. Furthermore, they have the potential to enhance
the effectiveness of schizophrenia treatment approaches by
helping to identify those patients who are most likely to respond
to a given treatment using surrogate markers of treatment
response. In this way, future interventions can be tailored to speci-
fic patient populations, thereby facilitating early intervention and
reducing medication non-response, adverse side effects and
non-compliance. The identified biomarkers could also serve as
candidate drug targets to improve efficacy of current antipsychotic
medications by add-on or novel treatments.
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